Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TMO
stocks logo

TMO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.95B
+4.87%
6.450
+5.74%
11.03B
+6.39%
5.598
+8.69%
11.48B
+5.73%
5.870
+9.52%
Estimates Revision
The market is revising Upward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by 0.84% over the past three months. During the same period, the stock price has changed by 16.78%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.84%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1%
In Past 3 Month
Stock Price
Go Up
up Image
+16.78%
In Past 3 Month
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 575.240
sliders
Low
561.00
Averages
615.44
High
675.00
Current: 575.240
sliders
Low
561.00
Averages
615.44
High
675.00
Argus
Buy
maintain
$580 -> $610
2025-10-29
Reason
Argus
Price Target
$580 -> $610
2025-10-29
maintain
Buy
Reason
Argus raised the firm's price target on Thermo Fisher to $610 from $580 and keeps a Buy rating on the shares after its "strong" Q3 earnings beat. The company is shrewdly deploying capital for M&A, facility expansions, and new product offerings such as AI tools, while the results also show that the end market conditions are improving, the analyst tells investors in a research note. Thermo Fisher's recently announced collaboration with OpenAI presents another growth opportunity, the firm added.
Morgan Stanley
NULL -> Overweight
maintain
$560 -> $656
2025-10-28
Reason
Morgan Stanley
Price Target
$560 -> $656
2025-10-28
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Thermo Fisher to $656 from $560 and keeps an Overweight rating on the shares after updating the firm's model following third quarter results last week.
UBS
Neutral
maintain
$500 -> $590
2025-10-23
Reason
UBS
Price Target
$500 -> $590
2025-10-23
maintain
Neutral
Reason
UBS raised the firm's price target on Thermo Fisher to $590 from $500 and keeps a Neutral rating on the shares. The firm's forward view is unchanged after Q3 sales growth was about in-line with expectations and profitability beat, the analyst tells investors in a post-earnings note.
TD Cowen
Buy
maintain
$612 -> $654
2025-10-23
Reason
TD Cowen
Price Target
$612 -> $654
2025-10-23
maintain
Buy
Reason
TD Cowen raised the firm's price target on Thermo Fisher to $654 from $612 and keeps a Buy rating on the shares. The firm said 3Q looked good with 5% EPS beat, organic roughly 0.5% better and the 2025 guide was raised (organic intact). Biopharma is the strongest market (MSD% 3Q growth) and getting stronger (biotech, PPD), supporting a better 2026.
Barclays
Overweight
maintain
$585 -> $625
2025-10-23
Reason
Barclays
Price Target
$585 -> $625
2025-10-23
maintain
Overweight
Reason
Barclays raised the firm's price target on Thermo Fisher to $625 from $585 and keeps an Overweight rating on the shares post the Q3 report. The company reported relatively solid results across the board, the analyst tells investors in a research note.
Citi
Patrick Donnelly
Neutral
maintain
$500 -> $580
2025-10-23
Reason
Citi
Patrick Donnelly
Price Target
$500 -> $580
2025-10-23
maintain
Neutral
Reason
Citi analyst Patrick Donnelly raised the firm's price target on Thermo Fisher to $580 from $500 and keeps a Neutral rating on the shares following the Q3 report. The firm says artificial intelligence drove the beat.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 24.10, compared to its 5-year average forward P/E of 24.10. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
24.10
Current PE
24.10
Overvalued PE
26.98
Undervalued PE
21.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
20.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
22.77
Undervalued EV/EBITDA
18.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.95
Current PS
0.00
Overvalued PS
5.57
Undervalued PS
4.33
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 154.71% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 154.71% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TMO News & Events

Events Timeline

(ET)
2025-12-02
17:10:00
Thermo Fisher Expands Bioprocessing Capabilities with New Center in India
select
2025-12-01 (ET)
2025-12-01
16:40:00
Morgan Stanley Assigns Overweight Rating to Thermo Fisher with $670 Price Target
select
2025-12-01
06:22:00
HSBC Upgrades Thermo Fisher to Buy with $670 Price Target
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04Benzinga
Thermo Fisher Collaborates with UK Company to Expand Genetic Screening for Heart Disease

  • Partnership Announcement: GENinCode PLC has formed a commercial partnership with Thermo Fisher Scientific Inc. to manufacture and distribute the CARDIO inCode-Score test, which assesses genetic risk for heart disease using DNA from saliva or blood samples.

  • Market Potential: The collaboration targets the U.S., Europe, the Middle East, and Africa, with significant market opportunities in cardiovascular devices, estimated at $22.8 billion in the U.S. and 12.5 billion euros in the EU.

  • Regulatory Progress: The CARDIO inCode-Score test has received New York State licensure and is expected to be included in the 2025 Clinical Laboratory Fee Schedule, with plans for FDA approval and expansion into the EMEA market.

  • Thermo Fisher's Recent Acquisition: Thermo Fisher recently acquired Clario Holdings for $8.875 billion to enhance its digital and data capabilities, aiming to improve efficiency in drug development and clinical research.

[object Object]
Preview
2.0
12-03NASDAQ.COM
ProShares UltraPro S&P 500 Sees Significant Influx of Capital

  • 52-Week Range of UPRO: UPRO's share price has a 52-week low of $45.88 and a high of $122.19, with the last trade recorded at $116.31.

  • Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), impacting the underlying assets.

  • Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

[object Object]
Preview
4.5
12-03SeekingAlpha
Thermo Fisher Scientific Expands Investment in Asia's Biopharmaceutical Sector

  • Expansion in Asia: Thermo Fisher Scientific is expanding its bioprocessing operations in Asia, responding to the growth of the biopharmaceutical industry in the region.

  • New and Expanded Facilities: The company is launching a new bioprocess design center in Hyderabad, India, and has expanded existing centers in Incheon, Korea, and Singapore to improve biomanufacturing efficiency and sustainability.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 575.24 USD — it has decreased -0.9 % in the last trading day.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s business?

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.

arrow icon

What is the price predicton of TMO Stock?

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 615.44 USD with a low forecast of 561.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

Thermo Fisher Scientific Inc revenue for the last quarter amounts to 11.12B USD, increased 4.94 % YoY.

arrow icon

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

Thermo Fisher Scientific Inc. EPS for the last quarter amounts to 4.28 USD, increased 0.94 % YoY.

arrow icon

What changes have occurred in the market's expectations for Thermo Fisher Scientific Inc (TMO)'s fundamentals?

The market is revising Upward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by 0.84% over the past three months. During the same period, the stock price has changed by 16.78%.
arrow icon

How many employees does Thermo Fisher Scientific Inc (TMO). have?

Thermo Fisher Scientific Inc (TMO) has 125000 emplpoyees as of December 05 2025.

arrow icon

What is Thermo Fisher Scientific Inc (TMO) market cap?

Today TMO has the market capitalization of 216.12B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free